Multi-peptide vaccines vialed as peptide mixtures can be stable reagents for use in peptide-based immune therapies. - Wikidata - wikimedia - TriplyDB

Multi-peptide vaccines vialed as peptide mixtures can be stable reagents for use in peptide-based immune therapies.

Multi-peptide vaccines vialed as peptide mixtures can be stable reagents for use in peptide-based immune therapies.

http://www.wikidata.org/entity/Q30436792

about

A randomized phase II trial of multiepitope vaccination with melanoma peptides for cytotoxic T cells and helper T cells for patients with metastatic melanoma (E1602)The present and future of peptide vaccines for cancer: single or multiple, long or short, alone or in combination?Immunogenicity for CD8+ and CD4+ T cells of 2 formulations of an incomplete freund's adjuvant for multipeptide melanoma vaccines.Potential target antigens for a universal vaccine in epithelial ovarian cancer.Adaptive Resistance to Immunotherapy Directed Against p53 Can be Overcome by Global Expression of Tumor-Antigens in Dendritic Cells.Immunological and clinical effects of vaccines targeting p53-overexpressing malignancies.Encapsulation of Hydrophilic and Hydrophobic Peptides into Hollow Mesoporous Silica Nanoparticles for Enhancement of Antitumor Immune Response.

P2860

Q30411499-053A18FE-737B-40E7-A2B8-12C4FE9E83C7 Q30425111-EBD3F8D7-EC9A-49A6-8B8A-C0BC3002C163 Q30429708-6E84D8D6-FE5C-4807-91E9-6D13B17AAF1A Q34159451-4F13B360-4735-456D-BF75-490C5BD0CE25 Q34292741-4A3FC6E8-C824-4919-AB13-013472A67235 Q34898280-CDA38792-0FB2-46D8-9111-8018E89AECD0 Q47730028-2D42EB03-C3EE-421E-BD40-8ADE2CA69A09

P2860

Multi-peptide vaccines vialed as peptide mixtures can be stable reagents for use in peptide-based immune therapies.

http://www.wikidata.org/entity/Q30436792

description

2009 nî lūn-bûn

@nan

2009 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Multi-peptide vaccines vialed ...... eptide-based immune therapies.

@ast

Multi-peptide vaccines vialed ...... eptide-based immune therapies.

@en

type

label

Multi-peptide vaccines vialed ...... eptide-based immune therapies.

@ast

Multi-peptide vaccines vialed ...... eptide-based immune therapies.

@en

prefLabel

Multi-peptide vaccines vialed ...... eptide-based immune therapies.

@ast

Multi-peptide vaccines vialed ...... eptide-based immune therapies.

@en

P1433

Q30436792-E7E57A80-53A2-4D21-9103-3042869B81FB

P1476

Q30436792-90A9688A-EC20-43C5-BFE1-FEC5FF0CDDEE

P2093

Q30436792-929BD269-1FEA-4C8E-92B8-EEC7B45C6ABA

Q30436792-CBB8FF99-AE72-4903-8838-A0E905627CB3

P2860

Q30436792-1D4AFCE3-BA05-4A8C-A579-F25BB5F07257

Q30436792-1D81E4C6-8C70-4524-B92A-57D07C10621F

Q30436792-2D0CA53D-8A36-455B-A875-3F40E694DB69

Q30436792-2D64072B-EACE-4006-8593-F702BCBDED72

Q30436792-5872E5BF-A3BA-4003-BAAD-195EF77F122A

Q30436792-70A1CCFB-EA73-4BC0-9E83-50523E94F029

Q30436792-73858A2A-44FE-4A0C-9FDD-8FB23E96634C

Q30436792-79C6AEBC-8015-434A-B4A7-7EB34521FDA2

Q30436792-7A0B054C-B8EB-4F1F-BF29-06528934ACF7

Q30436792-AE790AF3-A246-48E1-AB13-5131721C2378

P304

Q30436792-5B027A16-BEDF-4008-AD3E-4960F90F9F25

P31

Q30436792-333A750D-92B7-4AEF-9539-A79F95C68EE4

P356

Q30436792-365EF6D0-BDB2-483A-898C-FA56E0720442

P407

Q30436792-69552D3F-FD8A-463D-B22D-D2A9796D15BC

P433

Q30436792-CA29E030-E2B7-4ED3-B1ED-38E9A17EF93C

P478

Q30436792-0C663D45-4575-470F-B0B0-990D3DF9B99E

P50

Q30436792-3ADFBBA1-654F-49E1-96FE-ED1D922917B4

Q30436792-69F14ED8-9C51-43FE-BB74-C0F66C0674AA

Q30436792-C3D94859-B028-43CC-B5A8-0EB9D80A2B13

P577

Q30436792-53D6F632-C38D-4052-9253-5EB9B733D436

P5875

Q30436792-249ABDC3-E494-49F3-B19C-00ABD7551DA0

P698

Q30436792-4FBCD8BC-D580-424E-884D-F725DCC8BE7C

P932

Q30436792-892097E1-2C1A-4C95-926F-74121C725C7B

P356

J.VACCINE.2009.01.018

P1433

P1476

Multi-peptide vaccines vialed ...... eptide-based immune therapies.

@en

P2093

John D Shannon

http://www.w3.org/2001/XMLSchema#string

Sarah T Lewis

http://www.w3.org/2001/XMLSchema#string

P2860

Evaluation of peptide vaccine immunogenicity in draining lymph nodes and peripheral blood of melanoma patients.

Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes.

Preventing the spontaneous modification of an HLA-A2-restricted peptide at an N-terminal glutamine or an internal cysteine residue enhances peptide antigenicity.

Immunologic and clinical outcomes of vaccination with a multiepitope melanoma peptide vaccine plus low-dose interleukin-2 administered either concurrently or on a delayed schedule.

Helper T-cell responses and clinical activity of a melanoma vaccine with multiple peptides from MAGE and melanocytic differentiation antigens.

Immunity to melanoma antigens: from self-tolerance to immunotherapy.

Immunologic and clinical outcomes of a randomized phase II trial of two multipeptide vaccines for melanoma in the adjuvant setting.

A multipeptide vaccine is safe and elicits T-cell responses in participants with advanced stage ovarian cancer.

A listing of human tumor antigens recognized by T cells: March 2004 update.

Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients

P304

1764-1770

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.VACCINE.2009.01.018

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P50

Nicholas E Sherman

Craig Slingluff

Kimberly A Chianese-Bullock

P577

2009-02-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23966810

http://www.w3.org/2001/XMLSchema#string

P698

19185050

http://www.w3.org/2001/XMLSchema#string

P932

2733525

http://www.w3.org/2001/XMLSchema#string